Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Summit Therapeutics (SMMT) Receivables - Other (2017 - 2025)

Summit Therapeutics filings provide 6 years of Receivables - Other readings, the most recent being $12000.0 for Q1 2025.

Quarterly Receivables - Other changed N/A to $12000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $12000.0 through Mar 2025, changed N/A year-over-year, with the annual reading at $574000.0 for FY2021, N/A changed from the prior year.
Receivables - Other hit $12000.0 in Q1 2025 for Summit Therapeutics, down from $90000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $1.1 million in Q2 2022 and bottomed at $12000.0 in Q1 2025.
Average Receivables - Other over 4 years is $397833.3, with a median of $322500.0 recorded in 2022.